October 2025
1. LI L, Wang Y, Du Z, Yu H, et al
   Hepatic aconitase 1 redirects citrate flux to suppress lipogenesis and ameliorate hypercholesterolemia.
   Metabolism. 2025 Oct 7:156417. doi: 10.1016/j.metabol.2025.156417.
   

   >> Share

   
   March 2025
2. DE MOURA DE SOUZA M, Mendes BX, Defante MLR, de Athayde de Hollanda Morais BA, et al
   Apolipoprotein C-III inhibitors for the treatment of hypertriglyceridemia: A meta-analysis of randomized controlled trials.
   Metabolism. 2025 Mar 10:156187. doi: 10.1016/j.metabol.2025.156187.
   

   >> Share

   
   July 2024
3. HAGVE M, Pereira SL, Walker DK, Engelen MPKJ, et al
   Statin treatment reduces leucine turnover, but does not affect endogenous production of beta-hydroxy-beta-methylbutyrate (HMB).
   Metabolism. 2024;156:155920.
   

   >> Share

   
   November 2023
4. ZUO F, Wang Y, Xu X, Ding R, et al
   CCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease.
   Metabolism. 2023 Nov 10:155724. doi: 10.1016/j.metabol.2023.155724.
   

   >> Share

   
   July 2023
5. WANG YD, Wu LL, Mai YN, Wang K, et al
   miR-32-5p induces hepatic steatosis and hyperlipidemia by triggering de novo lipogenesis.
   Metabolism. 2023 Jul 12:155660. doi: 10.1016/j.metabol.2023.155660.
   

   >> Share

   
   April 2023
6. LARSSON SC, Michaelsson K, Mola-Caminal M, Hoijer J, et al
   Corrigendum to "Genome-wide association and Mendelian randomization study of fibroblast growth factor 21 reveals causal associations with hyperlipidemia and possibly NASH" [Metab Volume 137, December 2022, 155329].
   Metabolism. 2023;143:155555.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share